Dr. Bekaii-Saab Discusses the Next Steps With Regorafenib in CRC

Tanios Bekaii-Saab, MD
Published: Tuesday, Apr 03, 2018



Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the next steps for regorafenib (Stivarga) in colorectal cancer (CRC).

Physicians are working on confirming the results of the REVERCE study in the United States, which revealed the superiority of sequencing regorafenib before cetuximab (Erbitux) in patients with metastatic CRC who progressed on standard chemotherapy, says Bekaii-Saab.

Physicians are building a proposal asking the same question of patients with metastatic CRC that a Japanese study asked regarding the sequencing of regorafenib in a United States population. This is to better understand whether moving regorafenib to an earlier line of therapy, before EGFR inhibitors, may indeed improve outcomes—similar to what was seen in the Japanese study.
 


Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the next steps for regorafenib (Stivarga) in colorectal cancer (CRC).

Physicians are working on confirming the results of the REVERCE study in the United States, which revealed the superiority of sequencing regorafenib before cetuximab (Erbitux) in patients with metastatic CRC who progressed on standard chemotherapy, says Bekaii-Saab.

Physicians are building a proposal asking the same question of patients with metastatic CRC that a Japanese study asked regarding the sequencing of regorafenib in a United States population. This is to better understand whether moving regorafenib to an earlier line of therapy, before EGFR inhibitors, may indeed improve outcomes—similar to what was seen in the Japanese study.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x